| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
(S)-(+)-ibuprofen treatment (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) decreased concentration-dependent cell survival in both cell lines to a comparable degree [2]. G0/G1 arrest and apoptosis are the outcomes of (S)-(+)-ibuprofen treatment (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) [2]. (S)-(+)-ibuprofen treatment (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) resulted in an increase in the cell cycle inhibitory protein p27Kip-1 and a downregulation of cyclins A and B [2]. Platelet aggregation, thromboxane production, and COX activity are all inhibited by (S)-(+)-ibuprofen [1]. (S)-(+)-Ibuprofen, with an IC50 of 61.7 μM, prevents NF-κB from activating upon T cell stimulation [3].
|
|---|---|
| ln Vivo |
In nude mice models, treatment with (15 mg/kg/day; i.p.; five days per week; for four weeks) suppresses the formation of tumors in HCA-7 and HCT-15 xenografts [2].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: HCT-15 and HCA-7 Cell Tested Concentrations: 0 µM, 200 µM, 400 µM, 600 µM, 700 µM, 800 µM, 900 µM and 1000 µM Incubation Duration: 8 days Experimental Results: Two The concentration-dependent decrease in cell viability was similar among the cell lines. Cell cycle analysis[2] Cell Types: HCT-15 and HCA-7 Cell Tested Concentrations: 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM and 1000 µM Incubation Duration: 24 hrs (hours) (HCT-15) or 20 hrs (hours) (HCA-7) Experimental Results: Causes G0/G1 phase obstruction. Apoptosis analysis[2] Cell Types: HCT-15 and HCA-7 Cell Tested Concentrations: 0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM and 1000 µM Incubation Duration: 72 hrs (hours) Experimental Results: Induction of apoptosis Death. Western Blot Analysis[2] Cell Types: HCT-15 and HCA-7 Cell Tested Concentrations: 900 µM Incubation Duration: 4 hrs (hours), 8 hrs (hours), 16 hrs (hours), 24 hrs (hours), 32 hrs (hours), 48 hrs (hours) and 72 hrs (hours) Experimental Results: Cyclin levels diminished D1 protein. |
| Animal Protocol |
Animal/Disease Models: NMRI (nu/nu) male mice (6-8 weeks old) injected with HCA-7 and HCT-15 cells [2]
Doses: 15 mg/kg/day Route of Administration: intraperitoneal (ip) injection; five days per week; continuous 4-week Experimental Results: Inhibition of tumor growth in mouse HCA-7 and HCT-15 xenografts. |
| References |
[1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.
[2]. Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33. [3]. N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52. |
| Molecular Formula |
C13H18O2
|
|---|---|
| Molecular Weight |
206.285
|
| Exact Mass |
206.1307
|
| CAS # |
51146-56-6
|
| Related CAS # |
Ibuprofen;15687-27-1;(S)-(+)-Ibuprofen-d3;1329643-44-8;(R)-(-)-Ibuprofen;51146-57-7;Ibuprofen sodium;31121-93-4;Ibuprofen-d3;121662-14-4
|
| SMILES |
OC([C@H](C1=CC=C(CC(C)C)C=C1)C)=O
|
| Synonyms |
L-669,455, MK 233 Dexibuprofen (free acid) MK-233Dexibuprofen Doctrin L 669455
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~484.78 mM)
Ethanol : ~100 mg/mL (~484.78 mM) H2O : ~1 mg/mL (~4.85 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (12.12 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: 10% EtOH + 90% Corn Oil Solubility in Formulation 6: 6.67 mg/mL (32.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8475 mL | 24.2377 mL | 48.4754 mL | |
| 5 mM | 0.9695 mL | 4.8475 mL | 9.6951 mL | |
| 10 mM | 0.4848 mL | 2.4238 mL | 4.8475 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
